ABBV-519
/ AbbVie
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
May 30, 2026
A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions and Subcutaneous Injections of ABBV-519 in Adult Participants With Systemic Lupus Erythematosus (SLE) or Rheumatoid Arthritis (RA)
(clinicaltrials.gov)
- P1 | N=30 | Recruiting | Sponsor: AbbVie | Not yet recruiting ➔ Recruiting
Adverse events • Enrollment open • First-in-human • Immunology • Inflammatory Arthritis • Lupus • Rheumatoid Arthritis • Rheumatology • Systemic Lupus Erythematosus • CRP
May 28, 2026
A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions and Subcutaneous Injections of ABBV-519 in Adult Participants With Systemic Lupus Erythematosus (SLE) or Rheumatoid Arthritis (RA)
(clinicaltrials.gov)
- P1 | N=30 | Not yet recruiting | Sponsor: AbbVie
Adverse events • First-in-human • New P1 trial • Immunology • Inflammatory Arthritis • Lupus • Rheumatoid Arthritis • Rheumatology • Systemic Lupus Erythematosus • CRP
1 to 2
Of
2
Go to page
1